Keyphrases
Hepatocellular Carcinoma
100%
Clinical Trials
100%
Clinical Research
33%
Clinical Benefit
33%
Phase II Trial
33%
Molecular Imaging
16%
Expert Panel
16%
Clinical Trial Design
16%
New Drugs
16%
Liver Disease
16%
Time to Progression
16%
Standard-of-care Therapy
16%
Composite Endpoint
16%
Recurrence Rate
16%
Disease-free Survival
16%
American Association for the Study of Liver Diseases
16%
Liver Function
16%
Barcelona Clinic Liver Cancer
16%
Phase II Study
16%
Progression-free Survival
16%
Control Arm
16%
Advanced Stage Disease
16%
Surrogate Marker
16%
Randomized Phase II Trial
16%
Cost-benefit
16%
Sorafenib
16%
Chemoembolization
16%
Neoadjuvant Setting
16%
Time-to-event
16%
Biomarker Imaging
16%
Child-Pugh A
16%
Common Framework
16%
Results Comparability
16%
Trial Execution
16%
Medicine and Dentistry
Hepatocellular Carcinoma
100%
Clinical Trial
100%
Disease
50%
Clinical Research
33%
Liver Disease
33%
Recurrent Disease
16%
Molecular Imaging
16%
Arm
16%
Population Research
16%
Biological Marker
16%
Progression Free Survival
16%
Disease Free Survival
16%
Clinical Study
16%
Liver Cancer
16%
Transcatheter Arterial Chemoembolization
16%
Liver Function
16%
Cancer Staging
16%
Disease Marker
16%
Cost Benefit Analysis
16%
Sorafenib
16%
Pharmacology, Toxicology and Pharmaceutical Science
Liver Cell Carcinoma
100%
Clinical Trial
100%
Disease
50%
Liver Disease
33%
Clinical Research
33%
Biological Marker
16%
Recurrent Disease
16%
Progression Free Survival
16%
Clinical Study
16%
Population Study
16%
Liver Cancer
16%
Cancer Staging
16%
Disease Marker
16%
Disease Free Survival
16%
Sorafenib
16%